Acromegaly and Gigantism Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Acromegaly and Gigantism Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Acromegaly and Gigantism Therapeutics market. The report identifies the key trends shaping and driving the global Acromegaly and Gigantism Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Acromegaly and Gigantism Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Acromegaly and Gigantism Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Acromegaly and Gigantism Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Acromegaly and Gigantism Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Acromegaly and Gigantism Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Acromegaly and Gigantism Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Acromegaly and Gigantism Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Acromegaly and Gigantism Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Acromegaly and Gigantism Therapeutics market landscape? – Identify, understand and capitalize.
Therapy Industry in the United Kingdom
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Acromegaly and Gigantism Therapeutics: Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 7
2.3 Etiology 8
2.4 Pathophysiology 9
2.5 Signs and Symptoms 10
2.6 Diagnosis 11
2.7 Treatment and Management Patterns for Acromegaly and Gigantism 11
2.8 GlobalData Pipeline Report Guidance 14
3 Acromegaly and Gigantism Therapeutics: Market Characterization 15
3.1 Acromegaly and Gigantism Therapeutics Market Size (2005-2010) – Global 15
3.2 Acromegaly and Gigantism Therapeutics Market Forecast (2010-2017) – Global 16
3.3 Acromegaly and Gigantism Therapeutics Market Size (2005-2010) – The US 18
3.4 Acromegaly and Gigantism Therapeutics Market Forecast (2010-2017) – The US 19
3.5 Acromegaly and Gigantism Therapeutics Market Size (2005-2010) – France 20
3.6 Acromegaly and Gigantism Therapeutics Market Forecast (2010-2017) – France 21
3.7 Acromegaly and Gigantism Therapeutics Market Size (2005-2010) – Germany 22
3.8 Acromegaly and Gigantism Therapeutics Market Forecast (2010-2017) – Germany 23
3.9 Acromegaly and Gigantism Therapeutics Market Size (2005-2010) – Italy 24
3.10 Acromegaly and Gigantism Therapeutics Market Forecast (2010-2017) – Italy 25
3.11 Acromegaly and Gigantism Therapeutics Market Size (2005-2010) – Spain 26
3.12 Acromegaly and Gigantism Therapeutics Market Forecast (2010-2017) – Spain 27
3.13 Acromegaly and Gigantism Therapeutics Market Size (2005-2010) – The UK 28
3.14 Acromegaly and Gigantism Therapeutics Market Forecast (2010-2017) – The UK 29
3.15 Acromegaly and Gigantism Therapeutics Market Size (2005-2010) – Japan 30
3.16 Acromegaly and Gigantism Therapeutics Market Forecast (2010-2017) – Japan 31
3.17 Drivers and Barriers for the Acromegaly and Gigantism Therapeutics Market 32
3.17.1 Drivers for the Acromegaly and Gigantism Therapeutics Market 32
3.17.2 Barriers for the Acromegaly and Gigantism Therapeutics Market 32
3.18 Opportunity and Unmet Need Analysis 33
3.19 Key Takeaway 34
4 Acromegaly and Gigantism Therapeutics:Competitive Assessment 35
4.1 Overview 35
4.2 Strategic Competitor Assessment 35
4.3 Product Profiles for the Major Marketed Products in the Acromegaly and Gigantism Therapeutics Market 37
4.3.1 Sandostatin (octreotide acetate) Injection 37
4.3.2 Sandostatin LAR Depot (octreotide acetate for injectable suspension) 37
4.3.3 Somatuline Depot (lanreotide) 38
4.3.4 Somavert (pegvisomant) 39
4.3.5 Bromocriptine Mesylate 40
4.4 Key Takeaway 41
5 Acromegaly and Gigantism Therapeutics: Pipeline Assessment 42
5.1 Overview 42
5.2 Strategic Pipeline Assessment 42
5.3 Acromegaly and Gigantism Therapeutics– Pipeline by Phases of Development 42
5.3.1 Acromegaly and Gigantism Therapeutics – Phase III Pipeline 43
5.3.2 Acromegaly and Gigantism Therapeutics – Phase II Pipeline 43
5.3.3 Acromegaly and Gigantism Therapeutics – Phase I Pipeline 43
5.3.4 Acromegaly and Gigantism Therapeutics – Pre-Clinical Pipeline 43
5.4 Acromegaly and Gigantism Therapeutics–Pipeline by Mechanism of Action 44
5.4.1 Technology Trends Analytic Framework 45
5.5 Acromegaly and Gigantism Therapeutics – Promising Drugs Under Clinical Development 46
5.6 Molecule Profile for Promising Drugs Under Clinical Development 46
5.6.1 Pasireotide LAR (SOM230) 46
5.6.2 Octreotide Implant 47
5.6.3 Octreotide (C2L) 48
5.7 Key Takeaway 49
6 Acromegaly and Gigantism Therapeutics: Clinical Trials Mapping 50
6.1 Clinical Trials by Region/Country 50
6.2 Clinical Trials by Phase 51
6.3 Clinical Trials by Trial Status 52
6.4 Clinical Trials Mapping by Sponsors 53
6.5 Clinical Trials Mapping by Prominent Sponsors 54
6.6 Top Companies Participating in Acromegaly and Gigantism Therapeutics Clinical Trials 55
7 Acromegaly and Gigantism Therapeutics: Strategic Assessment 56
7.1 Key Events Impacting the Future Market 56
7.2 Acromegaly and Gigantism Therapeutics: Implications for Future Market Competition 57
8 Acromegaly and Gigantism Therapeutics: Future Players 58
8.1 Introduction 58
8.2 Company Profiles 59
8.2.1 Novartis AG 59
8.2.2 Endo Pharmaceuticals Holding Inc. 60
8.2.3 Teijin Pharma Limited 61
8.2.4 Ambrilia Biopharma Inc. 62
8.2.5 Other Companies in the Acromegaly and Gigantism Therapeutics Market 63
9 Acromegaly and Gigantism Therapeutics: Licensing and Partnership Deals 65
10 Acromegaly and Gigantism Therapeutics: Appendix 66
10.1 Market Definitions 66
10.2 Abbreviations 66
10.3 Methodology 67
10.3.1 Coverage 67
10.3.2 Secondary Research 67
10.3.3 Forecasting 68
10.3.4 Primary Research 70
10.3.5 Expert Panel Validation 70
10.4 Contact Us 70
10.5 Disclaimer 70
10.6 Bibliography 71
1.1 List of Tables
Table 1: Somatostatin Analogues 12
Table 2: Acromegaly and Gigantism Therapeutics Market, Global, Revenue ($m), 2005–2010 16
Table 3: Acromegaly and Gigantism Therapeutics Market, Global, Forecast ($m), 2010–2017 17
Table 4: Acromegaly and Gigantism Therapeutics Market, The US, Revenue ($m), 2005–2010 18
Table 5: Acromegaly and Gigantism Therapeutics Market, The US, Forecasts ($m), 2010–2017 19
Table 6: Acromegaly and Gigantism Therapeutics Market, France, Revenue ($m), 2005–2010 20
Table 7: Acromegaly and Gigantism Therapeutics Market, France, Forecasts ($m), 2010–2017 21
Table 8: Acromegaly and Gigantism Therapeutics Market, Germany, Revenue ($m), 2005–2010 22
Table 9: Acromegaly and Gigantism Therapeutics Market, Germany, Forecasts ($m), 2010–2017 23
Table 10: Acromegaly and Gigantism Therapeutics Market, Italy, Revenue ($m), 2005–2010 24
Table 11: Acromegaly and Gigantism Therapeutics Market, Italy, Forecasts ($m), 2010–2017 25
Table 12: Acromegaly and Gigantism Therapeutics Market, Spain, Revenue ($m), 2005–2010 26
Table 13: Acromegaly and Gigantism Therapeutics Market, Spain, Forecasts ($m), 2010–2017 27
Table 14: Acromegaly and Gigantism Therapeutics Market, The UK, Revenue ($m), 2005–2010 28
Table 15: Acromegaly and Gigantism Therapeutics Market, The UK, Forecasts ($m), 2010–2017 29
Table 16: Acromegaly and Gigantism Therapeutics Market, Japan, Revenue ($m), 2005–2010 30
Table 17: Acromegaly and Gigantism Therapeutics Market, Japan, Forecasts ($m), 2010–2017 31
Table 18: Acromegaly and Gigantism Therapeutics – Phase III Pipeline, 2011 43
Table 19: Acromegaly and Gigantism Therapeutics – Phase II Pipeline, 2011 43
Table 20: Acromegaly and Gigantism Therapeutics – Phase I Pipeline, 2011 43
Table 21: Acromegaly and Gigantism Therapeutics – Pre-clinical Pipeline, 2011 43
Table 22: Acromegaly and Gigantism Therapeutics – Most Promising Drugs Under Clinical Development, 2011 46
Table 23: Acromegaly and Gigantism Therapeutics – Clinical Trials by Country, 2011 50
Table 24: Acromegaly and Gigantism Therapeutics – Clinical Trials by Phase, 2011 51
Table 25: Acromegaly and Gigantism Therapeutics – Clinical Trials by Status, 2011 52
Table 26: Acromegaly and Gigantism Therapeutics – Overall Sponsors, 2011 53
Table 27: Acromegaly and Gigantism Therapeutics – Prominent Sponsors, 2011 54
Table 28: Acromegaly and Gigantism Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 55
Table 29: Novartis AG – Acromegaly and Gigantism, Pipeline, 2011 60
Table 30: Endo Pharmaceuticals Holding Inc. – Hormonal Disorder, Pipeline, 2011 61
Table 31: Teijin Pharma Limited- Acromegaly and Gigantism, Pipeline, 2011 62
Table 32: Ambrilia Biopharma Inc.–Hormonal Disorder, Pipeline, 2011 63
Table 33: Acromegaly and Gigantism Therapeutics Market – Future Players 63
Table 34: Acromegaly and Gigantism, Global, Deals, 2011 65
1.2 List of Figures
Figure 1: Regulation of GHRH, Somatostatin and IGF-1 and Feedback Mechanism 9
Figure 2: Treatment Algorithm with Sandostatin and Sandostatin LAR Depot 12
Figure 3: Acromegaly and Gigantism Therapeutics Market, Global, Revenue ($m), 2005–2010 15
Figure 4: Acromegaly and Gigantism Therapeutics Market, Global, Forecast ($m), 2010–2017 17
Figure 5: Acromegaly and Gigantism Therapeutics Market, The US, Revenue ($m), 2005–2010 18
Figure 6: Acromegaly and Gigantism Therapeutics Market, The US, Forecast ($m), 2010–2017 19
Figure 7: Acromegaly and Gigantism Therapeutics Market, France, Revenue ($m), 2005–2010 20
Figure 8: Acromegaly and Gigantism Therapeutics Market, France, Forecast ($m), 2010–2017 21
Figure 9: Acromegaly and Gigantism Therapeutics Market, Germany, Revenue ($m), 2005–2010 22
Figure 10: Acromegaly and Gigantism Therapeutics Market, Germany , Forecast ($m), 2010–2017 23
Figure 11: Acromegaly and Gigantism Therapeutics Market, Italy, Revenue ($m), 2005–2010 24
Figure 12: Acromegaly and Gigantism Therapeutics Market, Italy, Forecast ($m), 2010–2017 25
Figure 13: Acromegaly and Gigantism Therapeutics Market, Spain, Revenue ($m), 2005–2010 26
Figure 14: Acromegaly and Gigantism Therapeutics Market, Spain, Forecast ($m), 2010–2017 27
Figure 15: Acromegaly and Gigantism Therapeutics Market, The UK, Revenue ($m), 2005–2010 28
Figure 16: Acromegaly and Gigantism Therapeutics Market, The UK, Forecast ($m), 2010–2017 29
Figure 17: Acromegaly and Gigantism Therapeutics Market, Japan, Revenue ($m), 2005–2010 30
Figure 18: Acromegaly and Gigantism Therapeutics Market, Japan, Forecast ($m), 2010–2017 31
Figure 19: Opportunity and Unmet Need in the Acromegaly and Gigantism Therapeutics Market 33
Figure 20: Acromegaly and Gigantism Therapeutics – Strategic Competitor Assessment, 2011 36
Figure 21: Acromegaly and Gigantism Therapeutics – Pipeline by Phase of Development, 2011 42
Figure 22: Acromegaly and Gigantism Therapeutics – Pipeline by Mechanism of Action, 2011 44
Figure 23: Acromegaly and Gigantism Therapeutics – Technology Trends Analytics Framework – Description, 2011 45
Figure 24: Acromegaly and Gigantism Therapeutics – Clinical Trials by Country, 2011 50
Figure 25: Acromegaly and Gigantism Therapeutics – Clinical Trials by Phase, 2011 51
Figure 26: Acromegaly and Gigantism Therapeutics – Clinical Trials by Status, 2011 52
Figure 27: Acromegaly and Gigantism Therapeutics – Overall Sponsors, 2011 53
Figure 28: Acromegaly and Gigantism Therapeutics – Prominent Sponsors, 2011 54
Figure 29: Acromegaly and Gigantism Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 55
Figure 30: Acromegaly and Gigantism Therapeutics Market, Drivers and Barriers 2011 56
Figure 31: Implications for Future Market Competition in the Acromegaly and Gigantism Market, 2011 57
Figure 32: Acromegaly and Gigantism Therapeutics Market – Pipeline by Company, 2011 58
Figure 33: GlobalData Market Forecasting Model 69
Companies mentioned
Novartis AG
Endo Pharmaceuticals Holding Inc.
Teijin Pharma Limited
Ambrilia Biopharma Inc.
